Figure 5: Loss of phospho-Y239/240-ShcA signalling increases PD-L1 expression on mammary tumours. | Nature Communications

Figure 5: Loss of phospho-Y239/240-ShcA signalling increases PD-L1 expression on mammary tumours.

From: The Shc1 adaptor simultaneously balances Stat1 and Stat3 activity to promote breast cancer immune suppression

Figure 5

(a) Relative PD-L1 mRNA levels normalized to Actb levels were determined by RT–quantitative PCR in control, STAT1-null or STAT3-null cells of the indicated genotypes: MT/ShcA+/+ (864), MT/Shc2F/2F (5372), MT/Shc313F/313F (6738)) that were cultured in the absence (PBS) or presence (0.2 ng ml−1) of IFNγ for 24 h. Data represented as mean±s.d. (b) Relative PD-L1 mRNA levels (normalized to Actb) in mammary tumours derived from MT/ShcA+/+, MT/Shc2F/2F and MT/Shc313F/313F transgenic mice (n=7 tumours per genotype)±s.e.m. (c) Relative PD-L1 mRNA levels (normalized to Actb) in mammary tumours from CD8+/+ and CD8−/− mice injected with breast cancer cells of the indicated genotypes: MT/ShcA+/+ (864), MT/Shc2F/2F (5372) and MT/Shc313F/313F (6738). Data represented as mean±s.e.m. (n=6 tumours each) (*P<0.05 and **P<0.01; unpaired two-tailed Student’s t-test for a and Wilcoxon’s rank-sum test for b,c).

Back to article page